TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) — Andrew Peller Limited (TSX: ADW.A / ADW.B) (“Andrew Peller” or the “Company“) is pleased to announce that the holders of Class A Shares and Class B Shares of the Company (collectively, the “Shareholders“) have approved the proposed plan of arrangement (the “Arrangement“) involving Fairfax Financial Holdings Limited (“Fairfax“), and 18013632 Canada Inc. (the “Purchaser“), a newly-formed and wholly-owned subsidiary of Fairfax, at the special meeting of Shareholders (the “Meeting“) held earlier today. Pursuant to the Arrangement, the Purchaser will acquire all of the issued and outstanding Class A Shares and Class B Shares of the Company (other than those shares held by John Peller and certain affiliates (the...

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) — NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) and Donlin Gold Holdings LLC (DGH), 100% wholly-owned by Paulson Advisers LLC and its affiliates (“Paulson”), are pleased to announce the appointment of Endeavour Financial (“Endeavour”), and Macquarie Capital (“Macquarie”) (collectively, the “Financial Advisors”) to provide financial advisory services for the development of the Donlin Gold project in Alaska and to support the arrangement of project and infrastructure financing. Strategy and Mandate As part of the mandate, the Financial Advisors will assist Donlin Gold in evaluating funding alternatives and executing a structured project financing strategy. They will coordinate engagement with potential financiers, advance select funding avenues,...

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026. The employees received non-qualified stock options to purchase an aggregate 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $9.28 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued...

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions. The Private Placement comprises the issuance of an aggregate of up to 700,001 Class A ordinary shares, par value $0.01 per share, of the Company...

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) and Rudin Management announced today that they have formally agreed to enter into a joint venture with an affiliate of Kenneth C. Griffin, Citadel’s Founder and CEO (“KG”), for the development of a 1.9 million square foot trophy office building at 350 Park Avenue. In connection with the development, Citadel Enterprise Americas LLC will enter into a 15-year, 1.05 million square foot anchor lease at the property to serve as its primary New York City office. The joint venture will be owned 60% by KG, 36% by Vornado and 4% by Rudin. The project development budget is expected to be approximately $6.2 billion, of which $3.3 billion will be financed through a construction loan. Taking into account Vornado’s $500 million land contribution to the joint venture,...

FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) — FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share (the “Offering”). All of the ADSs in the proposed Offering will be sold by the Company. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the Offering on the same terms and conditions. The terms of the ADSs to be issued in the Offering are to be determined upon pricing of the Offering. The Offering is subject to market conditions,...

FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) — FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Company’s HIFU segment, reported as continuing operations, for the second quarter of 2026.  During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company’s operations and financial results....